Navigation Links
Discovery could help to develop drugs for organ transplant and cancer patients
Date:4/13/2012

MAYWOOD, Ill. -- Loyola researchers are reporting surprising findings about a molecule that helps ramp up the immune system in some cases and suppress it in others.

The finding eventually could lead to new drugs to regulate the immune system by, for example, revving it up to attack tumor cells or tamping it down to prevent the rejection of transplanted organs.

The study is published online ahead of print in the Journal of Immunology. Senior author is Makio Iwashima, PhD, an associate professor in the Department of Microbiology & Immunology of Loyola University Chicago Stritch School of Medicine. Co-authors are Robert Love, MD, a professor in the Departments of Thoracic & Cardiovascular Surgery and Microbiology & Immunology and one of the world's leading lung transplant surgeons, and first author Mariko Takami, PhD, of the Department of Microbiology & Immunology.

The immune system relies on a balancing act between two types of cells. Effector cells attack tumor cells and cells infected by viruses or bacteria. Regulatory cells suppress the immune system so that it does not attack healthy tissue. If effector cells are too active, an individual can suffer autoimmune disorders such as lupus, Type 1 diabetes and multiple sclerosis. But if regulatory cells are too active, the immune system will not be aggressive enough to protect the individual from germs and cancer.

The study involved an immune system molecule called transforming growth factor beta (TGF-β). TGF-β is known to be a powerful regulator of the immune response -- generally suppressing the strength of the response. In this study, however, Loyola researchers demonstrated that TGF-β can amplify the immune response and result in a more effective targeted response under specific conditions.

"TGF-β is a double-edged sword," Iwashima said. "It augments immune system reactions but does not determine what direction they will take. Depending on conditions, these reactions can either activate or suppress the immune system."

The study involved mouse cells grown ex vivo in laboratory dishes. The next steps will be to study TGF-β in human cells and in animal models. Understanding the dual role of TGF-β could help in the development of drugs to either activate or suppress the immune system, as needed, Iwashima said.


'/>"/>

Contact: Jim Ritter
jritter@lumc.edu
708-216-2445
Loyola University Health System
Source:Eurekalert

Related medicine news :

1. Washingtons Life Sciences Discovery Fund awards commercialization grants
2. Scientist awarded $1 million grant to develop tools for hepatitis C treatment discovery
3. New discovery of proteins involved in positioning muscular nuclei
4. Cell signaling discovery provides new hope for blood disorders
5. Gene mutation discovery sparks hope for effective endometriosis screening
6. Discovery predicts patient sensitivity to important drug target in deadly brain cancer
7. Discovery of new vaccine approach for treatment of cancer
8. Zebrafish may help speed drug discovery
9. Unexpected discovery opens up new opportunities for targeting cancer
10. Journal names discovery that HIV treatment can prevent spread breakthrough of the year
11. Salk discovery may lead to safer treatments for asthma, allergies and arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... , ... April 24, 2017 , ... My T Chai, ... its products are now available for purchase on RevNutrition.com, a popular website specializing in ... first produced and popularized in ancient India and Siam. It spread across Asia and ...
(Date:4/24/2017)... ... April 24, 2017 , ... symplrTM, a leading ... today announced that Kyle Allain has joined the company as Vice President and ... operations, including provider, payor and managed care solutions. , A seasoned executive ...
(Date:4/24/2017)... ... 24, 2017 , ... In 2017, up to 78,000 new ... of them will be malignant.(1) As research into precision medicine continues, both patients ... in the diagnosis and treatment of brain tumors. Healthcare facilities that are already ...
(Date:4/24/2017)... ... 2017 , ... Rod Burkett, CEO of Gardant Management Solutions, was recently featured ... at the forefront of Gardant since it was founded in 1999. His drive and ... of more than 40 new senior living communities. With his leadership, Gardant has grown ...
(Date:4/24/2017)... ... ... As a former supermodel known for her timeless beauty, Joan Severance knows ... is that she put all the words in her new book, "Manifest Your Mate: ... and sparkling sense of humor have inspired her to write a book on how ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... , April 19, 2017  Novartis today announced ... National Heart, Lung, and Blood Institute (NHLBI) of ... 58% of patients with treatment-na├»ve severe aplastic anemia ... treated with eltrombopag at the initiation of and ... study evaluated three sequential treatment groups, or cohorts. ...
(Date:4/18/2017)... Cogentix Medical, Inc. (NASDAQ: CGNT), a global ... and Gynecology markets with innovative and proprietary products, will ... 31, 2017 after the market close on Tuesday, May ... a conference call and webcast to discuss its financial ... at 4:30 p.m. Eastern Time (3:30 p.m. Central Time). ...
(Date:4/18/2017)...  Astute Medical, Inc., developer of biomarkers for better ... at the 2017 National Kidney Foundation (NKF) Spring ... April 22. Physicians will present data on two biomarkers, ... for acute kidney injury (AKI) during the management of ... Elevated levels of TIMP-2 and IGFBP-7 have been ...
Breaking Medicine Technology: